The Retinal Vein Occlusion Market to Grow with a CAGR of 6.39% for the Study Period 2017-30

- Increase in Retinal vein occlusion market will be due to rise in the geriatric population, enhanced market penetration of emerging therapies, readily uptake of current as well as emerging drugs with convenient to patient RoA, & increased awareness.

LAS VEGAS, Dec. 23, 2020 /PRNewswire/ -- DelveInsight's Retinal vein occlusion (RVO) market report delivers an in-depth understanding of the RVO, historical and forecasted epidemiology as well as the Retinal vein occlusion market trends, current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Retinal vein occlusion market size, unmet needs, drivers and barriers in the 7MM  (the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan) for the study period 2017-30.

Request for the sample report @ Retinal vein occlusion market landscape

Few key highlights of the Retinal vein occlusion drug market

• The current Retinal vein occlusion treatment market is dependent on anti-VEGF, corticosteroids, laser therapy, and other off-labelled therapies. 
• Anti-VEGF (including ranibizumab, aflibercept, and bevacizumab) dominates the entire RVO market owing to the greatest improvement they offer. 
• Laser therapy and steroids account for around 5-10% of the total RVO market share. 
• The present Retinal vein occlusion drug market comprises only three FDA-approved products for RVO treatment namely Lucentis (ranibizumab, Genentech), Eylea (aflibercept, Regeneron), and Ozurdex (dexamethasone intravitreal implant, Allergan Pharmaceuticals).
• The uptake of Avastin (bevacizumab) owing to its cost-effectiveness is also significant in the RVO treatment market as an off-label treatment option. 
• Emerging pipeline therapies such as Brolucizumab, ONS-5010, TLC399, AR-1105, and GB-102 are expected to push the market growth considerably during the forecast period 2020-30. 
• TLC399, AR-1105, and GB-102 are in phase II clinical development and are expected to enter the Retinal vein occlusion market in the forecast period (2020–2030). 
• The emerging pipeline therapies are expected to face stiff competition from the presently dominated Anti-VEGF therapies and corticosteroids. 

Retinal vein occlusion is the second most common cause of blindness from retinal vascular disease after diabetic retinopathy. It often causes a sudden, painless reduction or loss of vision in older people.

According to DelveInsight's epidemiological analysis, the total Retinal vein occlusion prevalent population in the 7MM is estimated to be 2,308,457 cases in 2020. It is estimated that the prevalence is expected to go on the continuous rise during the study period 2017–2030. Gender-specific prevalence analysis observed a higher female prevalence as compared to males. 

The Retina vein occlusion epidemiology and market report provides historical and forecasted insights into the epidemiology of the disorder segmented into:

• Total Retinal vein occlusion prevalent cases
• Diagnosed Retinal vein occlusion prevalent cases
• Gender-specific Diagnosed Retinal vein occlusion prevalent cases 
• Age-specific Diagnosed Retinal vein occlusion prevalent cases 
• Type-specific Diagnosed Retinal vein occlusion prevalent cases and 
• Retinal vein occlusion treated cases

To know how epidemiological trends are changing upto 2030 in 7MM take a glance@ Retinal vein occlusion epidemiology trends snapshot 

Retinal Vein Occlusion Market Insights

The present Retinal vein occlusion treatment market includes Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs, Intravitreal injection of corticosteroid drugs, Intraocular injections of steroids, Focal laser therapy, Pan-retinal photocoagulation therapy, and Surgical treatment (such as radial optic neurotomy, chorioretinal venous anastomosis, vitrectomy with or without internal limiting membrane peeling). The major goal of treatment remains to stabilize vision by sealing off leaking blood vessels. The available therapies aim to prevent further visual loss and its complications, such as macular edema, ischemia, or neovascularization.This condition often leads to permanent changes in the vision. No treatment option can unblock the retinal veins. The outcome of the treatment also remains unpredictable as in some patients, vision may come back. It has been estimated that about one-third of the cases experience some improvement, about one-third stay the same, and the remaining one-third gradually improve, but it can take a year or more to learn the outcome.

There is no denying that a lot has been achieved to improve the quality of life of patients suffering from RVO, however, despite the advances in pharmacologic therapy, many eyes with RVO continue to lose vision. 

The current treatment options only are able to minimize the damage and do not improve vision loss in the long term. Thus, there is a requirement for further research for RVO treatments that may focus on neuroprotective and photoreceptor regeneration therapies to improve sight in patients who have limited vision due to RVO. Key players including Novartis, Annexin Pharmaceuticals, Gene Signal, Ocular Therapeutics, and Asclepix Therapeutics, among others, are investigating their candidates in different stages of clinical development for the treatment of Retinal vein occlusion. 

The emerging RVO drug pipeline possesses potential drugs as monotherapies as well as combination therapies that are anticipated to fuel the market size growth. Looking at the present unmet needs prevalent in the Retinal vein occlusion market, the need for the treatment regimen that focuses on restoration of the vision and at the same time is affordable. No doubt that with the entry of biosimilars in the Retinal vein occlusion market, the market growth is expected to experience a dip in the forecasted period 2020-30, along with the fear of the failure of the investigation products in the trials at the later stage of development, which can also put breaks in the growth of the RVO market size.

However, besides emerging therapies, high awareness regarding the symptoms, diagnosis, treatment, and management of the condition among the patients and physicians due to the better availability of advanced healthcare resources are expected to give a decent push to the RVO market size despite the presence of a few barriers. Overall, the Retinal vein occlusion therapeutics market is further expected to increase in the forecast period (2020–2030).

Retinal vein occlusion Marketed Therapies

• Lucentis (ranibizumab): Genentech
• Ozurdex (dexamethasone intravitreal implant): Allergan Pharmaceuticals
• Eylea (aflibercept): Regeneron
• Avastin (Off labelled)

Retinal vein occlusion Pipeline Therapies 

• Brolucizumab (RTH258/ESBA1008): Novartis Pharmaceuticals 
• TLC399 (ProDex): Taiwan Liposome Company 
• AR1105: Aerie Pharmaceuticals
• GB-102: Graybug Vision
• ONS5010/Lytenava (bevacizumab): Outlook Therapeutics 

Request for the walkthrough of the report@ Retinal vein occlusion market insights

Scope of the Report

• Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
• Markets Segmentation: By Geographies, By Therapies (Forecasted + Historical).
• Companies Covered: Novartis Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Gene Signal International, AsclepiX Therapeutics, Regeneron Pharmaceuticals, Genentech, Allergan, Outlook Therapeutics and others 
• Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis.
• Case Studies
• KOL's Views
• Analyst's View

Table of Contents 

Related Reports 

Central Retinal Vein Occlusion Market

DelveInsight's "Central Retinal Vein Occlusion - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Central Retinal Vein Occlusion, historical and forecasted epidemiology as well as the Central Retinal Vein Occlusion market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Age Related Macular Degeneration Market 

DelveInsight's "Age Related Macular Degeneration - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Age-Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vernal keratoconjunctivitis Market 

DelveInsight's "Vernal keratoconjunctivitis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Vernal keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Allergic Rhino Conjunctivitis Market

DelveInsight's "Allergic Rhino-Conjunctivitis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Allergic Rhino-Conjunctivitis, historical and forecasted epidemiology as well as the Allergic Rhino-Conjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Allergic Conjunctivitis Market

DelveInsight's "Allergic Conjunctivitis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Allergic Conjunctivitis, historical and forecasted epidemiology as well as the Allergic Conjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Central Serous Chorioretinopathy Market

DelveInsight's "Central Serous Chorioretinopathy Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Central Serous Chorioretinopathy, historical and forecasted epidemiology as well as the Central Serous Chorioretinopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Choroidal Neovascularization Market

DelveInsight's "Choroidal Neovascularization Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Choroidal Neovascularization, historical and forecasted epidemiology as well as the Choroidal Neovascularization market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us:

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg